This document provides a summary of Douglas Ivey's expertise and qualifications. Ivey has extensive experience in molecular discovery, genetics, and biochemistry. He has a Ph.D. in Microbiology and Molecular Genetics and has worked on projects involving drug screening, vaccine development, and identifying genetic mutations and proteins in various organisms. Ivey has strong technical skills and is well-suited for leading high-value research projects.

1. DOUGLAS IVEY, Ph.D.
San Francisco, CA
MOLECULAR DISCOVERY / GENETICS / BIOCHEMISTRY
My expertise is in molecular discovery. Prior accomplishments include the development and implementation of
a live cell-based high-throughput drug screening platform, vaccine candidate discovery in mice and the
identification and characterization of genetic mutations (created through random and site-directed mutagenesis)
and proteins (both structural and enzymatic) on multiple platforms including bacteria, yeast, filamentous fungi,
the protozoan parasite, Toxoplasma, and in mice.
My technical savvy, strong work ethic, creativity and dogged determination make me an ideal, hit-the-ground-
running candidate for championing high value projects.
RELEVANT EXPERTISE AND ACCOMPLISHMENTS
◆ Discovered, characterized and investigated protein targets in the parasite Toxoplasma through
yeast two-hybrid screening, genomic and protein database mining, and mass spec analysis of affinity-
purified multi-protein complexes.
◆ Developed and implemented a live yeast-based high-throughput screening platform, and
multiple secondary assays (cytokine-detecting ELISA’s / kinetic analysis) to identify and develop
isoform-specific inhibitors and activators of human cAMP and cGMP phosphodiesterases for
therapeutic use.
◆ Generated, designed, managed, and mined large chemical compound datasets for lead
generation and development. Developed chemical inventory procedures and protocols.
◆ Routinely performed detailed molecular analysis of proteins, post-translational modifications,
protein-protein binding motifs, drug interaction mechanisms (kinetic analysis), and small molecules
using a combination of immunoassays, molecular biology, genetic and biochemical tools.
◆ Developed and implemented an expression library DNA immunization protocol and procedure
to isolate and characterize fungal vaccine candidates in mice.
EDUCATION
UNIVERSITY OF TEXAS MEDICAL SCHOOL-HOUSTON
Ph.D., Microbiology and Molecular Genetics, 1999
UNIVERSITY OF HOUSTON-DOWNTOWN
B.S., Applied Microbiology, 1993
FELLOWSHIPS AND AWARDS
NIH Kirschstein National Research Service Award, 2003-2006
Ewing Halsell Foundation Grant, 2000
Graduate School of Biomedical Sciences Travel Awards, 1995-1998
18th and 19th International Fungal Genetics Conference Travel Awards, 1995 and 1997
Excellence in Microbiology Award, University of Houston-Downtown, 1993

2. F. Douglas Ivey, Ph.D. Curriculum vitae
RESEARCH EXPERIENCE
BOSTON COLLEGE
Molecular architecture and mechanisms of Toxoplasma gondii cellular division. Laboratory of Professor Marc-
Jan Gubbels, May 2009-Sept 2010.
The obligate intracellular parasite Toxoplasma gondii divides by an internal budding process wherein
two daughter cells form within the mother. The cytoskeleton of the parasite is complex, and serves as a
scaffold for daughter cell assembly. Using a combination of genetics (i.e., yeast two-hybrid screens) and
proteomics, I identified enzymes and proteins that interact with an essential and dynamic component of
the contractile ring that is required during daughter cell maturation. My recent work focused on a family
of phosphatases that participate with, and modify MORN1 during cytokinesis.
BOSTON COLLEGE
Discover, develop and commercialize small molecule regulators of cyclic nucleotide phosphodiesterases. Co-
Founder of Fission Pharmaceuticals, LLC with Prof. Charles S. Hoffman, 2006-2009.
Developed fission yeast-based high throughput screen for mammalian and Trypanosomal
PDE inhibitors and validated this screening platform on over 400,000 compound-enzyme
combinations at the Broad Institute. Designed and implemented a versatile compound
database through a collaboration with BC bioinformaticians. Developed novel
techniques to allow working with cGMP-specific PDEs, despite the apparent absence of
cGMP signaling in fission yeast. Discovered the first small molecule activators of cAMP
PDEs. Demonstrated that PDE7A/B and PDE4A/B subtype selective inhibitors retain
therapeutic anti-inflammatory effects in tissue culture models. Played a central role
initiating collaborations with academic laboratories interested in testing PDE
inhibitors/activators in animal models for tumor metastasis, diffuse large B cell
lymphomas, HIV/SIV infection and replication, apoptosis of human lymphoma cell lines,
and compound-protein co-crystallization studies. Co-Founded Fission Pharmaceuticals,
LLC and acted as CSO.
BOSTON COLLEGE
Genetic analysis of G protein signaling in Schizosaccharomyces pombe. Ruth L. Kirschstein National Research
Service Award, Laboratory of Prof. Charles S. Hoffman, 2002-2006.
Defined protein-protein interactions, and structure-function relationships that govern G
protein-mediated signal transduction of the glucose signaling pathway. This work led to
the identification of a Gα (Gpa2) binding site on the Schizosaccharomyces pombe
adenylate cyclase enzyme and was the first work to describe a direct physical interaction
between a Gα subunit and adenylate cyclase in any fungal system.
In a parallel project, a genetic screen was conducted to isolate mutant Gα alleles that
promoted Gβγ-independent activation of the glucose/cAMP signaling pathway. Thirteen
novel, constitutively activated Gα variants were identified and characterized by in vivo
and in vitro assays. These experiments provide details into the mechanism of Gα
activation and define critical residues within Gα proteins that were previously unrealized.
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER-SAN ANTONIO
Valley Fever vaccine development. Postdoctoral Fellow, Laboratory of Prof. Rebecca A. Cox, 1999-2002.
At the South Texas Center for Biotechnology in Medicine, with Profs. Rebecca Cox and
Mitch Magee, I focused on vaccine development against the highly pathogenic fungus,
Coccidioides immitis, the agent of Valley Fever. I championed a procedure called
Expression Library Immunization and isolated a gene, ELI-Ag1, that protected mice

3. F. Douglas Ivey, Ph.D. Curriculum vitae
against a lethal challenge with C. immitis spores when administered as a DNA-based
vaccine.
UNIVERSITY OF TEXAS MEDICAL SCHOOL-HOUSTON
“Functional analysis of GNA-1, a Gαi superfamily member found in the filamentous fungus Neurospora
crassa.” Ph.D. Dissertation, Laboratory of Prof. Katherine A. Borkovich, 1993-1999.
My dissertation focused on G protein-mediated sensing in fungi. I provided the first
biochemical evidence, in any fungal system, for positive regulation of adenylate cyclase
by GNA-1. Discovered a mechanism by which intracellular cAMP levels are maintained
by compensatory mechanisms involving a balance between PDE and adenylate cyclase
activities. Reconstituted G protein-regulated adenylate cyclase activity through mixing
experiments between G protein and adenylate cyclase mutant membrane extracts.
UNIVERSITY OF TEXAS MEDICAL SCHOOL-HOUSTON
Study of the expression of the early genes, E2 and E4, of Human Papilloma Virus 2a. Laboratory of A.J.
Bednarz-Prashad, MD, Ph.D., Undergraduate Senior Honors Elective, 1992-1993
My first research experience focused on restriction mapping, DNA subcloning, tissue
culture, and performing Northern analyses to determine the order of expression of HPV
2a early genes.

4. F. Douglas Ivey, Ph.D. Curriculum vitae
PUBLICATIONS
Demirbas, D., Ceyhan, O., Wyman, A., Ivey, F.D., Allain, C., Wang, L., Sharuk, M.N., Francis, S.H., and
Hoffman, C.S. “Use of a Schizosaccharomyces pombe PKA-repressible reporter to study cGMP metabolising
phosphodiesterases.” Cellular Signalling (23):594-601, 2011.
Anderson-White, B.R., Ivey, F.D., Cheng, K., Szatanek, T., Lorestani, A., Beckers, C.J., Ferguson, D.J.P.,
Sahoo, N. and Gubbels, M.J. “A family of intermediate filament-like proteins is sequentially assembled into the
cytoskeleton of Toxoplasma gondii.” Cellular Microbiology, 13(1):18-31, 2011.
Ivey, F.D., Taglia, F.X., Yang, F., Lander, M.M., Kelly, D.A., Hoffman, C.S. “Activated Alleles of the
Schizosaccharomyces pombe gpa2+ Gα Gene Identify Residues Involved in GDP-GTP Exchange.” Eukaryotic
Cell. 9(4):626-33, 2010.
Alaamery, M.A. Wyman, A.R., Ivey, F.D., Allain, C., Demirbas, D., Wang, L., Ceyhan, O., Hoffman, C.S.
“New classes of PDE7 inhibitors identified by a fission yeast-based HTS.” Journal of Biomolecular Screening
15(4):359-67, 2010.
Ivey, F.D. *, Wang, L. *, Demirbas, D., Allain, C.A., and Hoffman, C.S. “Development of a fission yeast-based
high throughput screen to identify chemical regulators of cAMP phosphodiesterases.” Journal of Biomolecular
Screening, 13(1):62-71, 2008.
Kao, R.S., Morreale, E., Wang, L., Ivey, F.D., and Hoffman, C.S. “Schizosaccharomyces pombe Git1 is a C2-
domain protein required for glucose activation of adenylate cyclase.” Genetics, 173:49-61, 2006.
Wang, L., Griffiths Jr., K., Zhang, Y.H., Ivey, F.D., and Hoffman, C.S. “Schizosaccharomyces pombe adenylate
cyclase suppressor mutations suggest a role for cAMP phosphodiesterase regulation in feedback control of
glucose/cAMP signaling.” Genetics, 171:1523-33, 2005.
Ivey, F.D. and Hoffman, C.S. “Direct activation of fission yeast adenylate cyclase by the Gpa2 Gα of the
glucose signaling pathway.” Proc Natl Acad Sci USA. 102(17):6108-13, 2005.
Wang, L., Kao, R., Ivey, F.D., and Hoffman, C.S. “Strategies for gene disruptions and plasmid constructions in
fission yeast.” Methods 33(3):199-205, 2004.
Ivey, F.D., Magee, D.M., Woitaske, M.D., Johnston, S.A., and Cox, R.A. “Identification of a protective antigen
of Coccidioides immitis by expression library immunization.” Vaccine 21:4359-4367, 2003.
Ivey, F.D. and Hoffman, C.S. “Pseudostructural inhibitors of G protein signaling during development.”
Developmental Cell (Preview) 3(2):154-5, 2002.
Jiang, C., Magee, D.M., Ivey, F.D., and Cox, R.A. “Role of signal sequence in vaccine-induced protection
against experimental coccidioidomycosis.” Infection and Immunity 70(7):3539-45, 2002.
Ivey, F.D., Kays, A.M., and Borkovich, K.A. “Shared and independent roles for a Gαi protein and adenylyl
cyclase in regulating development and stress responses in Neurospora crassa." Eukaryotic Cell. 1(4):634-642,
2002.
Ivey, F.D., Yang, Q., and Borkovich, K.A. “Positive regulation of adenylyl cyclase activity by a Gαi
homologue in Neurospora crassa.” Fungal Genetics and Biology 26:48-61, 1999.

5. F. Douglas Ivey, Ph.D. Curriculum vitae
Ivey, F.D. *, Hodge, P.N. *, Turner, G.E., and Borkovich, K.A. “The Gαi homologue gna-1 controls multiple
differentiation pathways in Neurospora crassa.” Molecular Biology of the Cell 7:1283-1297, 1996. * equal
contributions
PATENTS
United States Patent No. 7,342.101 B1 “Compositions and Methods Comprising a Protective Antigen of
Coccidioides immitis.” R.A. Cox, D.M. Magee, F.D. Ivey, and M.D. Woitaske. Issued March 11, 2008.
Application no. 12/426,171 “Inhibitors of cyclic AMP Phosphodiesterases.” Charles S. Hoffman, F. Douglas
Ivey and Arlene Wyman Petri. Filed April 17, 2009.
TEACHING EXPERIENCE
BOSTON COLLEGE
Advanced Molecular Biology Laboratory Course. Spring 2006
Trained and supervised laboratory personnel. 2002-present
UNIVERSITY OF TEXAS MEDICAL SCHOOL-HOUSTON
Teaching Assistant in Medical Microbiology. 1993-1996
UNIVERSTY OF HOUSTON-DOWNTOWN
Teaching Assistant in Microbiology, Medical Microbiology, Techniques in Recombinant DNA, and
Biochemistry. 1991-1993
INVITED TALKS
“Mining G protein structure-function via genetic analysis in Schizosaccharomyces pombe.” The Second East
Coast Regional Fission Yeast Meeting, Miami, FL, 2005.
“Glucose signaling in Schizosaccharomyces pombe: The Gpa2-adenylyl cyclase connection.” Platform
presentation. 2004 Yeast Genetics and Molecular Biology Meeting, University of Washington, Seattle.
“Vaccine development against Coccidioides immitis," San Antonio Microbiologist Conference, Kerrville, TX,
2001.
“Heterotrimeric G proteins in Neurospora crassa," Neurospora 1998, Pacific Grove, CA.
“Properties of a Neurospora crassa gna-1 Gαi deletion mutant," Developmental control of gene expression and
protein modulation meeting, Stanford University, Palo Alto, CA, 1996.

6. F. Douglas Ivey, Ph.D. Curriculum vitae
REFERENCES
Available on Request